Formycon AG (0W4N.L)
0W4N.L Stock Price Chart
Explore Formycon AG interactive price chart. Choose custom timeframes to analyze 0W4N.L price movements and trends.
0W4N.L Company Profile
Discover essential business fundamentals and corporate details for Formycon AG (0W4N.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
29 Jan 2018
Employees
250.00
Website
https://www.formycon.comCEO
Stefan Glombitza
Description
Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
0W4N.L Financial Timeline
Browse a chronological timeline of Formycon AG corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Earnings released on 13 Aug 2025
Revenue for the quarter reached €9.00M , missing expectations by -35.71%.
Earnings released on 12 May 2025
EPS came in at -€6.54 , while revenue for the quarter reached €42.78M , beating expectations by +205.58%.
Earnings released on 28 Nov 2024
EPS came in at -€0.58 , while revenue for the quarter reached €26.89M , missing expectations by -7.27%.
Earnings released on 8 May 2024
EPS came in at €4.61 , while revenue for the quarter reached €33.91M .
Earnings released on 30 Jun 2023
EPS came in at €0.11 , while revenue for the quarter reached €43.79M , missing expectations by -0.48%.
Earnings released on 31 Dec 2022
EPS came in at -€2.91 , while revenue for the quarter reached €24.85M , missing expectations by -0.59%.
Earnings released on 30 Jun 2022
EPS came in at €6.41 , while revenue for the quarter reached €17.64M , missing expectations by -0.50%.
Dividend declared on 15 Mar 2022
A dividend of €0.29 per share was announced, adjusted to €0.29.
Earnings released on 31 Dec 2021
EPS came in at -€0.30 , while revenue for the quarter reached €16.66M .
Earnings released on 30 Jun 2021
EPS came in at -€0.92 , while revenue for the quarter reached €20.31M .
Earnings released on 31 Dec 2020
EPS came in at -€0.41 , while revenue for the quarter reached €17.72M .
0W4N.L Stock Performance
Access detailed 0W4N.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.